27306062|t|Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response
27306062|a|Individual response to interferon beta (IFN-β) 1a treatment is heterogeneous in multiple sclerosis (MS). Our objective was to find a connection between serum levels of interleukin (IL)-10, IL-17 and transforming growth factor beta (TGF-β)1 in MS patients treated with IFN-β in order to identify the nonresponders (NR). We included in the study 32 healthy subjects and 32 MS patients: 10 naive, 10 early treated and 12 late treated with INF-β1a. Serum determination of cytokines and brain MRI were performed at the beginning of the study, after 6 and 12 months. Rio score was calculated at the end of the study. MS patients had initially a significant higher level of IL-17 and a lower level of TGF-β1 compared to healthy subjects. IL-17 level in early treated patients was significantly lower compared to the naive and late treated groups. INF-β1a treatment significantly increased IL-10 and decreased IL-17 levels. Initial low levels of IL-10 were associated with an increase in physical disability. IL-17 levels positively correlated with the number of relapses and MRI activity. Nine patients were NR to Avonex. Patients with a Rio score of 3 had higher initial levels of IL-17 and those with a Rio score of 0 had higher initial levels of IL-10 and TGF-β1. IFN-β1a decreased IL-17 and increased IL-10 seric levels; IL-17 significantly correlated with MS activity; TGF-β1 activity is titer-dependent, increased levels were associated with IL-17 inhibition; NR patients to IFN-β1a will have initial high IL-17 and low IL-10 and TGF-β seric levels.
27306062	14	29	Interleukin-17A	T103	UMLS:C1705947
27306062	31	45	Interleukin-10	T103	UMLS:C0085295
27306062	50	82	Transforming Growth Factor-Beta1	T103	UMLS:C1704256
27306062	83	88	Serum	T031	UMLS:C0229671
27306062	119	137	Multiple Sclerosis	T038	UMLS:C0026769
27306062	160	166	Avonex	T103	UMLS:C0594372
27306062	168	176	Possible	T033	UMLS:C0332149
27306062	177	187	Biomarkers	T201	UMLS:C0005516
27306062	192	210	Treatment Response	T201	UMLS:C0521982
27306062	211	221	Individual	T098	UMLS:C0237401
27306062	222	230	response	T201	UMLS:C0521982
27306062	234	260	interferon beta (IFN-β) 1a	T103	UMLS:C0254119
27306062	291	309	multiple sclerosis	T038	UMLS:C0026769
27306062	311	313	MS	T038	UMLS:C0026769
27306062	320	329	objective	T170	UMLS:C0018017
27306062	344	354	connection	T082	UMLS:C0449379
27306062	363	368	serum	T031	UMLS:C0229671
27306062	379	398	interleukin (IL)-10	T103	UMLS:C0085295
27306062	400	405	IL-17	T103	UMLS:C0384648
27306062	410	450	transforming growth factor beta (TGF-β)1	T103	UMLS:C1704256
27306062	454	456	MS	T038	UMLS:C0026769
27306062	479	484	IFN-β	T103	UMLS:C0015980
27306062	497	505	identify	T033	UMLS:C0243095
27306062	510	523	nonresponders	T033	UMLS:C0243095
27306062	525	527	NR	T033	UMLS:C0243095
27306062	549	554	study	T062	UMLS:C0008972
27306062	558	574	healthy subjects	T098	UMLS:C1708335
27306062	582	584	MS	T038	UMLS:C0026769
27306062	647	654	INF-β1a	T103	UMLS:C0254119
27306062	656	661	Serum	T031	UMLS:C0229671
27306062	662	675	determination	T058	UMLS:C1148554
27306062	679	688	cytokines	T103	UMLS:C0079189
27306062	693	702	brain MRI	T058	UMLS:C0412675
27306062	742	747	study	T062	UMLS:C0008972
27306062	815	820	study	T062	UMLS:C0008972
27306062	822	824	MS	T038	UMLS:C0026769
27306062	878	883	IL-17	T103	UMLS:C0384648
27306062	905	911	TGF-β1	T103	UMLS:C1704256
27306062	924	940	healthy subjects	T098	UMLS:C1708335
27306062	942	947	IL-17	T103	UMLS:C0384648
27306062	1043	1049	groups	T098	UMLS:C0687744
27306062	1051	1058	INF-β1a	T103	UMLS:C0254119
27306062	1093	1098	IL-10	T103	UMLS:C0085295
27306062	1113	1118	IL-17	T103	UMLS:C0384648
27306062	1149	1154	IL-10	T103	UMLS:C0085295
27306062	1191	1210	physical disability	T038	UMLS:C0520817
27306062	1212	1217	IL-17	T103	UMLS:C0384648
27306062	1279	1282	MRI	T058	UMLS:C0024485
27306062	1312	1314	NR	T033	UMLS:C0243095
27306062	1318	1324	Avonex	T103	UMLS:C0594372
27306062	1386	1391	IL-17	T103	UMLS:C0384648
27306062	1453	1458	IL-10	T103	UMLS:C0085295
27306062	1463	1469	TGF-β1	T103	UMLS:C1704256
27306062	1471	1478	IFN-β1a	T103	UMLS:C0254119
27306062	1489	1494	IL-17	T103	UMLS:C0384648
27306062	1509	1514	IL-10	T103	UMLS:C0085295
27306062	1515	1520	seric	T031	UMLS:C0229671
27306062	1529	1534	IL-17	T103	UMLS:C0384648
27306062	1565	1567	MS	T038	UMLS:C0026769
27306062	1578	1584	TGF-β1	T103	UMLS:C1704256
27306062	1652	1657	IL-17	T103	UMLS:C0384648
27306062	1670	1672	NR	T033	UMLS:C0243095
27306062	1685	1692	IFN-β1a	T103	UMLS:C0254119
27306062	1716	1721	IL-17	T103	UMLS:C0384648
27306062	1730	1735	IL-10	T103	UMLS:C0085295
27306062	1740	1745	TGF-β	T103	UMLS:C0040690
27306062	1746	1751	seric	T031	UMLS:C0229671